Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZL
Status:
RECRUITING
Trial end date:
2031-06-01
Target enrollment:
Participant gender:
Summary
This is an open-label, multicenter, phase 2, non-randomized study aiming to evaluate the efficacy and safety of orelabrutinib combined with zebetuzumab and lenalidomide or bendamustine combined with rituximab in the treatment of newly diagnosed marginal zone lymphoma (MZL).
Phase:
PHASE2
Details
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University